Literature DB >> 9738054

Assessment of hepatitis C virus sequence complexity by electrophoretic mobilities of both single-and double-stranded DNAs.

Y M Wang1, S C Ray, O Laeyendecker, J R Ticehurst, D L Thomas.   

Abstract

To assess genetic variation in hepatitis C virus (HCV) sequences accurately, we optimized a method for identifying distinct viral clones without determining the nucleotide sequence of each clone. Twelve serum samples were obtained from seven individuals soon after they acquired HCV during a prospective study, and a 452-bp fragment from the E2 region was amplified by reverse transcriptase PCR and cloned. Thirty-three cloned cDNAs representing each specimen were assessed by a method that combined heteroduplex analysis (HDA) and a single-stranded conformational polymorphism (SSCP) method to determine the number of clonotypes (electrophoretically indistinguishable cloned cDNAs) as a measure of genetic complexity (this combined method is referred to herein as the HDA+SSCP method). We calculated Shannon entropy, incorporating the number and distribution of clonotypes into a single quantifier of complexity. These measures were evaluated for their correlation with nucleotide sequence diversity. Blinded analysis revealed that the sensitivity (ability to detect variants) and specificity (avoidance of false detection) of the HDA+SSCP method were very high. The genetic distance (mean +/- standard deviation) between indistinguishable cloned cDNAs (intraclonotype diversity) was 0.6% +/- 0.9%, and 98.7% of cDNAs differed by <2%, while the mean distance between cloned cDNAs with different patterns was 4.0% +/- 3.2%. The sensitivity of the HDA+SSCP method compared favorably with either HDA or the SSCP method alone, which resulted in intraclonotype diversities of 1.6% +/- 1.8% and 3.5% +/- 3.4%, respectively. The number of clonotypes correlated strongly with genetic diversity (R2, 0.93), but this correlation fell off sharply when fewer clones were assessed. This HDA+SSCP method accurately reflected nucleotide sequence diversity among a large number of viral cDNA clones, which should enhance analyses to determine the effects of viral diversity on HCV-associated disease. If sequence diversity becomes recognized as an important parameter for staging or monitoring of HCV infection, this method should be practical enough for use in laboratories that perform nucleic acid testing.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738054      PMCID: PMC105098     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  45 in total

1.  Marked sequence diversity in the putative envelope proteins of hepatitis C viruses.

Authors:  N Kato; Y Ootsuyama; T Tanaka; M Nakagawa; T Nakazawa; K Muraiso; S Ohkoshi; M Hijikata; K Shimotohno
Journal:  Virus Res       Date:  1992-02       Impact factor: 3.303

Review 2.  The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance--a review.

Authors:  E Domingo; E Martínez-Salas; F Sobrino; J C de la Torre; A Portela; J Ortín; C López-Galindez; P Pérez-Breña; N Villanueva; R Nájera
Journal:  Gene       Date:  1985       Impact factor: 3.688

Review 3.  Selforganization of matter and the evolution of biological macromolecules.

Authors:  M Eigen
Journal:  Naturwissenschaften       Date:  1971-10

4.  Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection.

Authors:  S A Villano; D Vlahov; K E Nelson; S Cohn; D L Thomas
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

5.  Typing of HLA-DQA1 and DQB1 using DNA single-strand conformation polymorphism.

Authors:  M Carrington; T Miller; M White; B Gerrard; C Stewart; M Dean; D Mann
Journal:  Hum Immunol       Date:  1992-03       Impact factor: 2.850

6.  Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.

Authors:  N Ogata; H J Alter; R H Miller; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

7.  Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins.

Authors:  A J Weiner; M J Brauer; J Rosenblatt; K H Richman; J Tung; K Crawford; F Bonino; G Saracco; Q L Choo; M Houghton
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

8.  Mutations of the KIT (mast/stem cell growth factor receptor) proto-oncogene account for a continuous range of phenotypes in human piebaldism.

Authors:  R A Spritz; S A Holmes; R Ramesar; J Greenberg; D Curtis; P Beighton
Journal:  Am J Hum Genet       Date:  1992-11       Impact factor: 11.025

9.  Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability.

Authors:  H Okamoto; M Kojima; S Okada; H Yoshizawa; H Iizuka; T Tanaka; E E Muchmore; D A Peterson; Y Ito; S Mishiro
Journal:  Virology       Date:  1992-10       Impact factor: 3.616

10.  Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.

Authors:  M Martell; J I Esteban; J Quer; J Genescà; A Weiner; R Esteban; J Guardia; J Gómez
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

View more
  18 in total

1.  Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees.

Authors:  S C Ray; Q Mao; R E Lanford; S Bassett; O Laeyendecker; Y M Wang; D L Thomas
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.

Authors:  Andrea L Cox; Timothy Mosbruger; Georg M Lauer; Drew Pardoll; David L Thomas; Stuart C Ray
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

3.  Non-obese diabetic mice select a low-diversity repertoire of natural regulatory T cells.

Authors:  Cristina Ferreira; Yogesh Singh; Anna L Furmanski; F Susan Wong; Oliver A Garden; Julian Dyson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

4.  Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies.

Authors:  Q Mao; S C Ray; O Laeyendecker; J R Ticehurst; S A Strathdee; D Vlahov; D L Thomas
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.

Authors:  K Sandres; M Dubois; C Pasquier; J L Payen; L Alric; M Duffaut; J P Vinel; J P Pascal; J Puel; J Izopet
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  Wide range of quasispecies diversity during primary hepatitis C virus infection.

Authors:  Belinda L Herring; Rose Tsui; Lorraine Peddada; Michael Busch; Eric L Delwart
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Multigene tracking of quasispecies in viral persistence and clearance of hepatitis C virus.

Authors:  Song Chen; Yu-Ming Wang
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

8.  Genetic evolution of structural region of hepatitis C virus in primary infection.

Authors:  Song Chen; Yu-Ming Wang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

9.  Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure.

Authors:  Rose Tsui; Belinda L Herring; Jason D Barbour; Robert M Grant; Peter Bacchetti; Alex Kral; Brian R Edlin; Eric L Delwart
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire.

Authors:  Matthias Wölfl; Alleluiah Rutebemberwa; Timothy Mosbruger; Qing Mao; Hong-mei Li; Dale Netski; Stuart C Ray; Drew Pardoll; John Sidney; Alessandro Sette; Todd Allen; Thomas Kuntzen; Daniel G Kavanagh; Jürgen Kuball; Philip D Greenberg; Andrea L Cox
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.